HUP0002386A2 - Emberi MP52 csont-morfogenetikus faktort tartalmazó liofilizált készítmény - Google Patents

Emberi MP52 csont-morfogenetikus faktort tartalmazó liofilizált készítmény

Info

Publication number
HUP0002386A2
HUP0002386A2 HU0002386A HUP0002386A HUP0002386A2 HU P0002386 A2 HUP0002386 A2 HU P0002386A2 HU 0002386 A HU0002386 A HU 0002386A HU P0002386 A HUP0002386 A HU P0002386A HU P0002386 A2 HUP0002386 A2 HU P0002386A2
Authority
HU
Hungary
Prior art keywords
bone morphogenetic
human
freeze
morphogenetic protein
dried composition
Prior art date
Application number
HU0002386A
Other languages
English (en)
Inventor
Hideki Ichikawa
Mitsuko Inagaki
Original Assignee
Hoechst Marion Roussel Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Ltd. filed Critical Hoechst Marion Roussel Ltd.
Publication of HUP0002386A2 publication Critical patent/HUP0002386A2/hu
Publication of HUP0002386A3 publication Critical patent/HUP0002386A3/hu
Publication of HU226554B1 publication Critical patent/HU226554B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Az emberi MP52 csont-morfogenetikus faktort 1:5-től 1:50-ig terjedőtömegarányban mannittal keverve és az így kapott oldatot liofilizálvaemberi MP52 csont-morfogenetikus faktort tartalmazó, stabilliofilizált készítményt állítanak elő. Az így kapott készítménytárolás során stabilis marad, nem színeződik, és a benne lévő humánMP52 csont-morfogenetikus faktor nem károsodik; a termék az oldatvisszaállításának alkalmával nem tapad össze és nem zsugorodik. Ó
HU0002386A 1997-01-30 1998-01-29 Freeze-dried composition of bone morphogenetic protein human mp52 HU226554B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1634997 1997-01-30
PCT/JP1998/000371 WO1998033514A1 (fr) 1997-01-30 1998-01-29 Composition lyophilisee de mp52 humaine de proteines morphogenetiques osseuses

Publications (3)

Publication Number Publication Date
HUP0002386A2 true HUP0002386A2 (hu) 2000-11-28
HUP0002386A3 HUP0002386A3 (en) 2002-09-30
HU226554B1 HU226554B1 (en) 2009-03-30

Family

ID=11913900

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002386A HU226554B1 (en) 1997-01-30 1998-01-29 Freeze-dried composition of bone morphogenetic protein human mp52

Country Status (22)

Country Link
EP (1) EP0972520B9 (hu)
JP (1) JP4209948B2 (hu)
KR (1) KR100548107B1 (hu)
CN (1) CN1152712C (hu)
AP (1) AP983A (hu)
AT (1) ATE302021T1 (hu)
AU (1) AU737595B2 (hu)
BR (1) BR9807537B1 (hu)
CA (1) CA2278546C (hu)
DE (1) DE69831223T9 (hu)
DK (1) DK0972520T3 (hu)
EA (1) EA001579B1 (hu)
ES (1) ES2244043T3 (hu)
HU (1) HU226554B1 (hu)
IL (2) IL130967A0 (hu)
NO (1) NO322334B1 (hu)
NZ (1) NZ336509A (hu)
PL (1) PL189381B1 (hu)
RS (1) RS49691B (hu)
SI (1) SI0972520T1 (hu)
TR (1) TR199901832T2 (hu)
WO (1) WO1998033514A1 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4388602B2 (ja) † 1997-02-07 2009-12-24 ストライカー コーポレイション マトリクスを含まない骨形成デバイス、移植片、およびその使用方法
WO2003030873A1 (en) * 2001-10-09 2003-04-17 Cellfactors Plc Therapeutic biological product and method for formation of new vascularised bone
CA2466947C (en) 2001-11-19 2012-05-22 Scil Technology Gmbh A homogeneously coated device having osteoinductive and osteoconductive properties
ATE322916T1 (de) 2002-09-10 2006-04-15 Scil Technology Gmbh Unter verringerter sauerstoffkonzentration mit einem osteoinduktiven protein beschichtetes metallimplantat
EP1651272A1 (en) * 2003-08-05 2006-05-03 Fuji Photo Film B.V. Use of recombinant or synthetic gelatin as a stabiliser in vaccines
CA2545458A1 (en) * 2003-11-10 2005-05-26 Arriva-Prometic Inc. Dry recombinant human alpha 1-antitrypsin formulation
JP4944010B2 (ja) 2004-03-10 2012-05-30 サイル テクノロジー ゲーエムベーハー コーティングされたインプラント、その製造および使用
US10360287B2 (en) 2015-05-22 2019-07-23 Microsoft Technology Licensing, Llc Unified messaging platform and interface for providing user callouts
US20160344677A1 (en) 2015-05-22 2016-11-24 Microsoft Technology Licensing, Llc Unified messaging platform for providing interactive semantic objects

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3273597D1 (en) * 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
AU663328B2 (en) * 1991-06-21 1995-10-05 Genetics Institute, Llc Pharmaceutical formulations of osteogenic proteins
JP2966592B2 (ja) * 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
UA48105C2 (uk) * 1992-02-12 2002-08-15 Біофарм Гезельшафт Цур Біотехнологішен Ентвіклунг Вон Фармака Мбх ФРАГМЕНТ ДНК, ЯКИЙ КОДУЄ БІЛОК РОДИНИ TGF-<font face="Symbol">b</font> (ВАРІАНТИ), РЕКОМБІНАНТНА МОЛЕКУЛА ДНК (ВАРІАНТИ), КЛІТИНА-ХАЗЯЇН (ВАРІАНТИ), СПОСІБ ОДЕРЖАННЯ БІЛКУ РОДИНИ TGF-<font face="Symbol">b</font> (ВАРІАНТИ), БІЛОК РОДИНИ TGF-<font face="Symbol">b</font> (ВАРІАНТИ), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), АНТИТІЛО АБО ФРАГМЕНТ АНТИТІЛА (ВАРІАНТИ), МОЛЕКУЛА КДНК (ВАРІАНТИ)
CA2093836A1 (en) * 1992-04-24 1993-10-25 Wayne Gombotz Biodegradable tgf-.beta. delivery system for bone regeneration
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
EP0814841B1 (en) * 1995-03-21 2001-12-05 Applied Research Systems ARS Holding N.V. Hcg liquid formulations
US7235527B2 (en) * 1995-04-19 2007-06-26 Biopharm Gesellschaft Zur Biotechnologieschen Entwicklung Von Pharmaka Mbh Protein and process for producing the same

Also Published As

Publication number Publication date
IL130967A0 (en) 2001-01-28
SI0972520T1 (sl) 2006-02-28
DE69831223T9 (de) 2006-12-07
EA199900694A1 (ru) 2000-04-24
WO1998033514A1 (fr) 1998-08-06
ES2244043T3 (es) 2005-12-01
CA2278546A1 (en) 1998-08-06
HUP0002386A3 (en) 2002-09-30
NO993702D0 (no) 1999-07-29
RS49691B (sr) 2007-12-31
DE69831223T2 (de) 2006-02-16
NO993702L (no) 1999-09-29
BR9807537A (pt) 2000-03-21
NZ336509A (en) 2001-03-30
KR20000070586A (ko) 2000-11-25
EP0972520B1 (en) 2005-08-17
ATE302021T1 (de) 2005-09-15
BR9807537B1 (pt) 2009-01-13
AU5679198A (en) 1998-08-25
DK0972520T3 (da) 2005-12-19
AP9901602A0 (en) 1999-09-30
KR100548107B1 (ko) 2006-02-02
DE69831223D1 (de) 2005-09-22
TR199901832T2 (xx) 1999-12-21
NO322334B1 (no) 2006-09-18
CN1244127A (zh) 2000-02-09
AU737595B2 (en) 2001-08-23
IL130967A (en) 2006-12-10
YU34999A (sh) 2002-08-12
JP4209948B2 (ja) 2009-01-14
EA001579B1 (ru) 2001-06-25
CA2278546C (en) 2008-04-01
EP0972520A4 (en) 2002-11-05
PL334852A1 (en) 2000-03-27
HU226554B1 (en) 2009-03-30
EP0972520A1 (en) 2000-01-19
CN1152712C (zh) 2004-06-09
AP983A (en) 2001-07-16
PL189381B1 (pl) 2005-07-29
EP0972520B9 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
EP1686172A3 (en) Myocardial grafts and cellular compositions useful for same
CA2259163A1 (en) Nt-3 and bdnf analogs having improved circulating life and/or absorption
MY118835A (en) Sustained release compositions and the process for their preparation
DE60038860D1 (de) Kosmetische zusammenzetzungen enthaltend fluoreszente aufheller
HUT72325A (en) Stabile, liophylised composition containing proteins and kit applicabe for dosing
WO1998014592A3 (en) Telomerase reverse transcriptase
ATA788275A (de) Bioaktiver verbundwerkstoff fuer prothetische zwecke bzw fuer dentalzwecke und in-vitro- -verfahren zur herstellung solcher bioaktiver verbundwerkstoffe
EP1025840A3 (en) Oral drug compositions and methods
PT1308170E (pt) Composição seca de factor sanguíneo que compreende trealose
BR9403783A (pt) Uso de uma composição cosmética
HUP0002386A2 (hu) Emberi MP52 csont-morfogenetikus faktort tartalmazó liofilizált készítmény
ID24520A (id) Analog-analog peptida lh-rh, penggunaannya dan komposisi farmasi yamg mengandungnya
ATE180409T1 (de) Kollagenzubereitung zur gesteuerten abgabe von wirkstoffen
TW364850B (en) Nematocidal compositions
DE59501795D1 (de) Verwendung von cyclischen Depsipeptiden mit 12 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 12 Ringatomen und Verfahren zu ihrer Herstellung
ES2010911A6 (es) Composicion cosmetica de maquillaje de las pestanas a base de cera y de hidrolizado de queratina, y procedimiento para fabricarla.
ID19428A (id) Komposisi komposisi asam amino dan pemakaiannya dalam penekanan kekebalan
AU6732190A (en) Use of guanidinoacetic acid to induce an increase of the creatine contents in muscles
DE69400342D1 (de) Verfahren zur Herstellung von 1,1,1,2-Tetrafluor-2-Chlorethan und Pentafluorethan
EP0863192A4 (en) HUMIDIFIER COMPOSITION, THIS CONTAINING BASE COMPOSITION AND COSMETIC MATERIAL OR EXTERNAL APPLICATION WHICH CONTAINS THIS HUMIDIFIER COMPOSITION
BR9303862A (pt) Mesofase esmetica preparada &#34;in vitro&#34; e composicao cosmetica
DE69435058D1 (de) Vektor zur vielfachklonierung, expressionsvektor und herstellung von fremdprotein mit expressionsvektor
EP0875236B8 (de) Verwendung einer wässrigen Zubereitung zur Behandlung keratinischer Fasern
AU9545398A (en) Perfume composition and use of organopolysiloxanes with aryl function as solubilising agents and emollients in perfume compositions
Nowick Model behaviour

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees